Chronic Myeloid Leukemia

and, Thoas Fioretos; Johansson, Bertil

doi:10.1002/9781118010136.ch7

Cited by 4 publications

(3 citation statements)

References 159 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The frequency of MDS/AML in such patients is in order of 2–10%. 9 , 10 , 11 Analyzing the bone marrow of our four patients, they did not show the morphologic features of MDS/AML. Lin et al 6 also showed no association with MDS/AML.…”

mentioning

confidence: 74%

Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells

Rocha

Otero

Padilha

et al. 2011

Blood Cancer Journal

View full text Add to dashboard Cite

mentioning

confidence: 74%

Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells

Rocha

Otero

Padilha

et al. 2011

Blood Cancer Journal

View full text Add to dashboard Cite

“…In addition, we identified the presence of trisomy 21 in one patient. This chromosome harbors the AML1 gene, with mutations associated with resistance to treatment in patients with CML and +21 [46,47]. Chromosome 3 is involved in two types of structural rearrangements affecting the chromosome region 3q27.…”

Section: Additional Chromosomal Abnormalities Acasmentioning

confidence: 99%

Patterns of chromosome abnormalities in a sample of Colombian patients with chronic myeloid leukemia

Largo-Peralta,

Rondón-Lagos,

Sánchez-Peñarete

et al. 2023

Universitas Scientiarum

View full text Add to dashboard Cite

Chronic Myeloid Leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, resulting from a translocation between chromosomes 9 and 22 that gives rise to the BCR-ABL1 fusion gene. The Ph chromosome is present in 95 % of CML cases. In 5 %-10 % of these cases Ph variants occur and, approximately 5 % of these cases present with additional chromosomal abnormalities (ACAs). In this work we describe the prevalence of chromosome abnormalities in a sample of Colombian CML patients. A descriptive cross-sectional study was conducted, analyzing cytogenetic and molecular data from 142 CML patients. Data were collected between 2016 and 2019 at the laboratory of Biogenética Diagnóstica S.A.S. Among the 142 patients were analyzed, 56 % were male, and the average age was 45 years. The Ph chromosome was observed in 81 % of the cases. Three-way chromosome variants involving chromosomes 3, 7, and 8 were detected. The most frequent additional chromosomal aberration was +der(22)t(9;22). Atypical patterns associated with poor prognosis were found, via FISH analyses, in 88.2 % of the patients. The BCR-ABL1 fusion gene was detected in 100 % of the 18 patients subjected RT-PCR tests. This retrospective study reveals intriguing findings regarding chromosomal abnormalities in Colombian patients with CML, including rare three-way chromosome variants and atypical FISH patterns associated with a poor prognosis.Further investigation is warranted to explore the clinical implications, prognosis, and survival outcomes associated with these cytogenetic findings in CML patients.

show abstract

“…Approximately 10%–12% of patients in chronic-phase CML (CP-CML) present with additional chromosomal aberrations (ACAs) at diagnosis 2. Recently different researchers have studied this subgroup, including European Leukemia Net (ELN)3 and have classified CML ACAs into “major” and “minor” route changes 4. The major route ACAs are the most common chromosomal abnormalities (>10% of cases with ACAs) and include trisomy 8, an extra Ph (1der(22)t(9;22) (q34;q11)), isochromosome 17(i(17)(q10)), trisomy 19 and ider(22)(q10)t(9;22) (q34;q11).…”

Section: Introductionmentioning

confidence: 99%

Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature

Sgherza

Abruzzese

Perla

et al. 2017

TCRM

View full text Add to dashboard Cite

Approximately 10%–12% of patients in chronic-phase chronic myeloid leukemia (CP-CML) have additional chromosomal aberrations at diagnosis; moreover, CML occurs in up to 10% of pregnancy-associated leukemias, with an annual incidence of 1 per 100,000 pregnancies. In this report we describe the case of a 36-year-old female with CP-CML diagnosed in the 18th week of pregnancy and with a new complex variant translocation t(4;9;22;21)(q24;q34;q11;q22) and an additional chromosomal aberration t(1;20)(p36;p11). In consideration of her pregnancy, the patient strictly monitored her blood cell count without any specific treatment. At 32 weeks of pregnancy, the patient delivered via cesarean section a healthy baby girl. After 10 days from childbirth, dasatinib was started at a standard dosage of 100 mg/day and 3 months later complete cytogenetic response and major molecular response were obtained, with the achievement of an optimal response according to European Leukemia Net recommendations and showing efficacy of this tyrosine kinase inhibitor (TKI) in the presence of a complex karyotype.

show abstract

Chronic Myeloid Leukemia

Cited by 4 publications

References 159 publications

Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells

Patients with chronic myeloid leukemia treated with imatinib who showed the appearance of clonal cytogenetic abnormalities in Philadelphia chromosome-negative cells

Patterns of chromosome abnormalities in a sample of Colombian patients with chronic myeloid leukemia

Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature

Contact Info

Product

Resources

About